INSIDER
01Overview02Daily Brief03Live04Congress05Corporate Insiders06Government Money07Political Influence08Institutions09Washington Network10Follow the Power11Disclosure Clock12AI Investigator13Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenMethodologyMatch reviewLaunch readiness
01Overview02Daily Brief03Live04Congress05Corporate Insiders06Government Money07Political Influence08Institutions09Washington Network10Follow the Power11Disclosure Clock12AI Investigator13Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenMethodologyMatch reviewLaunch readiness
OverviewDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 46m ago
HOUSE PTR6m ago
SEC 13F5m ago
ROBINHOOD CHAIN5m ago
Public company

SYRESpyre Therapeutics, Inc.

CIK 0001636282

EDGAR filingsOpen in network
Disclosed transactions27
Buys / sells0 / 13
Max Insider Score28
Connections9with evidence

SYRE · disclosed activity on price

Disclosed transactions

ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
26
AW
Albers Jeffrey W.Director
SYRESpyre Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$1.05M
10.0K sh
Aug 7, 2026Aug 10, 2026
traded Aug 7, 2026
+3dSEC FORM 4

Evidence

Verified connections

  • In industryevidence
    Pharmaceuticals, devices & health servicesSEC SIC 2834 · Pharmaceutical Preparations · Nov 4, 2026
  • ← Lobbied forevidence
    ARNOLD & PORTER KAYE SCHOLER LLPLDA Q1 2026 first quarter · Health issues · Aug 26, 2026
  • ← Insider ofevidence
    Albers Jeffrey W.Director · Aug 10, 2026
  • ← Insider ofevidence
    Milligan SandraDirector · May 29, 2026
3
AW
Albers Jeffrey W.Director
SYRESpyre Therapeutics, Inc.
Option exercise · 10b5-1 plan
M
—
5,000 sh
Aug 7, 2026
Aug 10, 2026
traded Aug 7, 2026
+3d
SEC FORM 4

Evidence

2
AW
Albers Jeffrey W.Director
SYRESpyre Therapeutics, Inc.
Option exercise · 10b5-1 plan
M$52K
5,000 sh
Aug 7, 2026Aug 10, 2026
traded Aug 7, 2026
+3dSEC FORM 4

Evidence

23
AW
Albers Jeffrey W.Director
SYRESpyre Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$522K
5,000 sh
Aug 7, 2026Aug 10, 2026
traded Aug 7, 2026
+3dSEC FORM 4

Evidence

19
AW
Albers Jeffrey W.Director
SYRESpyre Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$835K
8,000 sh
Aug 7, 2026Aug 10, 2026
traded Aug 7, 2026
+3dSEC FORM 4

Evidence

5
BL
Burrows Scott LChief Financial Officer
SYRESpyre Therapeutics, Inc.
Option exercise
M—
15.0K sh
Jun 25, 2026Jun 26, 2026
traded Jun 25, 2026
+1dSEC FORM 4

Evidence

27
BL
Burrows Scott LChief Financial Officer
SYRESpyre Therapeutics, Inc.
Open-market sale
SELL$871K
10.0K sh
Jun 25, 2026Jun 26, 2026
traded Jun 25, 2026
+1dSEC FORM 4

Evidence

12
BL
Burrows Scott LChief Financial Officer
SYRESpyre Therapeutics, Inc.
Option exercise
M$218K
15.0K sh
Jun 25, 2026Jun 26, 2026
traded Jun 25, 2026
+1dSEC FORM 4

Evidence

23
BL
Burrows Scott LChief Financial Officer
SYRESpyre Therapeutics, Inc.
Open-market sale
SELL$436K
5,000 sh
Jun 25, 2026Jun 26, 2026
traded Jun 25, 2026
+1dSEC FORM 4

Evidence

9
MS
Milligan SandraDirector
SYRESpyre Therapeutics, Inc.
Grant or award
A—
8,026 sh
May 27, 2026May 29, 2026
traded May 27, 2026
+2dSEC FORM 4

Evidence

6
BL
Burrows Scott LChief Financial Officer
SYRESpyre Therapeutics, Inc.
Option exercise · 10b5-1 plan
M$181K
12.5K sh
May 1, 2026May 1, 2026
traded May 1, 2026
+0dSEC FORM 4

Evidence

20
BL
Burrows Scott LChief Financial Officer
SYRESpyre Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$892K
12.5K sh
May 1, 2026May 1, 2026
traded May 1, 2026
+0dSEC FORM 4

Evidence

0
BL
Burrows Scott LChief Financial Officer
SYRESpyre Therapeutics, Inc.
Option exercise · 10b5-1 plan
M—
12.5K sh
May 1, 2026May 1, 2026
traded May 1, 2026
+0dSEC FORM 4

Evidence

8
SS
Sloan SheldonChief Medical Officer
SYRESpyre Therapeutics, Inc.
Option exercise · 10b5-1 plan
M$2.15M
78.3K sh
May 1, 2026May 1, 2026
traded May 1, 2026
+0dSEC FORM 4

Evidence

27
SS
Sloan SheldonChief Medical Officer
SYRESpyre Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$1.48M
21.3K sh
May 1, 2026May 1, 2026
traded May 1, 2026
+0dSEC FORM 4

Evidence

27
SS
Sloan SheldonChief Medical Officer
SYRESpyre Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$1.39M
19.7K sh
May 1, 2026May 1, 2026
traded May 1, 2026
+0dSEC FORM 4

Evidence

24
SS
Sloan SheldonChief Medical Officer
SYRESpyre Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$628K
8,777 sh
May 1, 2026May 1, 2026
traded May 1, 2026
+0dSEC FORM 4

Evidence

24
SS
Sloan SheldonChief Medical Officer
SYRESpyre Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$932K
12.8K sh
May 1, 2026May 1, 2026
traded May 1, 2026
+0dSEC FORM 4

Evidence

28
SS
Sloan SheldonChief Medical Officer
SYRESpyre Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$764K
10.4K sh
May 1, 2026May 1, 2026
traded May 1, 2026
+0dSEC FORM 4

Evidence

28
SS
Sloan SheldonChief Medical Officer
SYRESpyre Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$377K
5,059 sh
May 1, 2026May 1, 2026
traded May 1, 2026
+0dSEC FORM 4

Evidence

22
SS
Sloan SheldonChief Medical Officer
SYRESpyre Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$30K
400 sh
May 1, 2026May 1, 2026
traded May 1, 2026
+0dSEC FORM 4

Evidence

7
SS
Sloan SheldonChief Medical Officer
SYRESpyre Therapeutics, Inc.
Option exercise · 10b5-1 plan
M—
78.3K sh
May 1, 2026May 1, 2026
traded May 1, 2026
+0dSEC FORM 4

Evidence

24
HT
Henderson Michael ThomasDirector
SYRESpyre Therapeutics, Inc.
Other acquisition or disposition
J—
63.2K sh
Jan 21, 2026Jan 23, 2026
traded Jan 21, 2026
+2dSEC FORM 4

Evidence

9
BL
Burrows Scott LChief Financial Officer
SYRESpyre Therapeutics, Inc.
Grant or award
A—
140.0K sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC FORM 4

Evidence

9
TC
Turtle CameronDirector, Chief Executive Officer
SYRESpyre Therapeutics, Inc.
Grant or award
A—
528.0K sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC FORM 4

Evidence

9
SS
Sloan SheldonChief Medical Officer
SYRESpyre Therapeutics, Inc.
Grant or award
A—
140.0K sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC FORM 4

Evidence

9
KH
King-Jones HeidySee Remarks
SYRESpyre Therapeutics, Inc.
Grant or award
A—
140.0K sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC FORM 4

Evidence

  • ← Insider ofevidence
    Henderson Michael ThomasDirector · Jan 23, 2026
  • ← Insider ofevidence
    King-Jones HeidySee Remarks · Jan 13, 2026
  • ← Insider ofevidence
    Sloan SheldonChief Medical Officer · Jan 13, 2026
  • ← Insider ofevidence
    Burrows Scott LChief Financial Officer · Jan 13, 2026
  • ← Insider ofevidence
    Turtle CameronDirector, Chief Executive Officer · Jan 13, 2026

    • Lobbying

    $50K reported · de-duplicated
    2026 Q2 $10K via firms2026 Q1 $40K via firms
    • ARNOLD & PORTER KAYE SCHOLER LLP$10K2026 Q2 · posted Aug 26, 2026 · Health issues
    • ARNOLD & PORTER KAYE SCHOLER LLP$40K2026 Q1 · posted Aug 26, 2026 · Health issues

    Connected PAC contributions

    FEC · direct to members

    No contributions from a PAC connected to this company.